The big problem with the HIV BLA is the combining of data from two trials. There will be the breakout and analysis from one trial, the breakout and analysis of relevant data from a second trial and then combining the data from both trials in a way that makes sense even though there are two different treatment/inclusion/exclusion protocols. A BLA for 350mg would have been simplicity itself in comparison.